Home
About Us
Pipeline
Partnerships
Investors
News & Events
Careers
| S*BIO Vision | Background | S*BIO Management | Board of Directors | Scientific Advisory Board | Corporate Values |
| Clinical Trials | Technologies & Capabilities |
| News & Press Releases | Participation in Events | Publications |
| Join Our Team | Career Opportunities |
 |
 |
|
The best scientist is open to experience and begins with romance - the idea that anything is possible. Ray Bradbury |
|
|
|
2008 Publications Journal of Computer-Aided Molecular Design 2008; 22(12): 897 – 906 Structure-based design of Aurora A & B inhibitors Anders Poulsen, Anthony William, Angeline Lee, Stephanie Blanchard, Eeling Teo, Weiping Deng, Noah Tu, Evelyn Tan, Eric Sun, Kay Lin Goh, Wai Chung Ong, Chee Pang Ng, Kee Chuan Goh and Zahid Bonday EORTC conference in Geneva, October 2008 SB939 chemistry: Discovery of SB939, an HDAC inhibitor with a superior preclinical profile (Abstract No. 136) Haishan Wang, Niefang Yu, Dizhong Chen, Eric T Sun, Kanda Sangthongpitag, Zahid Bonday, Pauline Yeo, Kantharaj Ethirajulu, Jeanette Wood and Brian Dymock EORTC conference in Geneva, October 2008 SB939 Phase 1 Study: A phase I dose escalation study of oral SB939 when administered thrice weekly (every other day) for 3 weeks in a 4-week cycle in patients with advanced solid malignancies (Abstract No. 413) Wei-Peng Yong, Boon-Cher Goh, Kantharaj Ethirajulu, Pauline Yeo, Odette Otheris, Siew Mien Chao, Ross Soo, Wee-Lee Yeo, Elaine Seah and Joy Zhu EORTC conference in Geneva, October 2008 SB939 Biomarker results: A robust and quantitative biomarker assay for SB939, a potent, orally-active HDAC inhibitor (Abstract No. 83) Veronica Novotny-Diermayr, Vasantha M. Nayagam, Hannes Hentze, Ai Leng Liang, Nina Sausgruber, Pauline Yeo, Kantharaj Ethirajulu, and Jeanette Wood UK-Singapore Medicinal Chemistry Symposium at Biopolis in Singapore, 16th October 2008 SB939 Oral Presentation: “SB939: the story of Singapore’s first home-grown small molecule oncology drug” Brian Dymock
|
